Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

NCT01015352 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Azacitidine
DRUG: Epoetin beta

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]
[object Object]